The FDA has approved six prescription weight-loss drugs for long-term use, plus one for rare genetic conditions.

Contrave (bupropion-naltrexone): A daily pill combining two medicines. Can raise blood pressure and may cause mood changes. Regular monitoring required.

Saxenda (liraglutide): A daily injection. Also treats diabetes at lower doses. Common side effects include nausea and vomiting.

Xenical (orlistat): A pill taken three times daily with meals. Blocks fat absorption. Available over-the-counter as Alli. Causes gas and loose stools. Requires a low-fat diet.

Qsymia (phentermine-topiramate): A once-daily pill. Phentermine is a controlled substance with low misuse risk. Can raise heart rate and blood pressure. Topiramate increases birth defect risk.

Wegovy (semaglutide): A weekly injection. Same drug as Ozempic and Rybelsus for diabetes. Side effects include nausea, diarrhea, and belly pain.

Zepbound (tirzepatide): A weekly injection. Same drug as Mounjaro for diabetes. Side effects include nausea, vomiting, diarrhea, and constipation.

Imcivree (setmelanotide): A daily injection for people age 6+ with obesity caused by rare inherited conditions. Helps patients eat less and feel full sooner.

Most of these medications work by reducing hunger or helping you feel full longer. Orlistat works by blocking fat absorption.

had good results with it. Treatment decisions should be individualized and made with appropriate medical guidance.

The first month on a GLP-1 medication is about adaptation, not dramatic weight loss. According to clinical guidance, average weight loss in the first 30 days is approximately 0.9 to 2.3 kg (about 2 to 5 pounds).

Most people will notice appetite changes within the first week, including increased fullness and reduced food cravings. However, significant scale movement typically doesn't happen until the dose is increased in subsequent months

Choosing the right option depends on your medical history, health goals, and advice from a qualified healthcare professional. We recommend consulting your doctor before starting any new weight management treatment.

Semaglutide targets GLP-1. Tirzepatide targets GLP-1 and GIP. Learn how these medications differ in mechanism and results.

The answer depends on whether you mean prescription GLP-1 pills or over-the-counter supplements. These are very different categories with vastly different evidence and safety profiles.

If You Mean Prescription GLP-1 Pills

The most effective FDA-approved oral GLP-1 for weight loss is oral semaglutide (Wegovy pill), which produces approximately 13.6% to 16.6% average weight loss when taken as directed. This is the only oral GLP-1 specifically approved for weight management as of early 2026.

A newer option, Foundayo (orforglipron), was approved in April 2026. Unlike the Wegovy pill, it can be taken any time of day, with or without food, making it more convenient. Clinical trials showed clinically meaningful weight reduction over 72 weeks, though specific percentage data was not provided in the available results.

New Harvard research suggests that losing weight on GLP-1 medications may improve employment outcomes for women entering the job market. The study, published as a working paper by economist Rebecca Diamond, analyzed data from the Understanding America Study and found that unemployed women were 26.9% more likely to find a job after 18 months on GLP-1 medications

The performance gap comes down to pharmacology. Semaglutide is a GLP-1 receptor agonist—it activates one hormone pathway that reduces appetite and slows gastric emptying.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway. This dual action appears to produce additive effects on appetite suppression, fat metabolism, and blood sugar regulation .

Think of it as activating two complementary braking systems on appetite and weight gain, rather than just one.